RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX), announced today that it launched its web site at www.RegeneRx.com. The site is designed to provide the general public with both historical and timely information regarding the company's business along with news releases as they occur. The site also features a compendium of publications and abstracts related to the company's technology.

RegeneRx is a biopharmaceutical company, founded in 1982, focused on products to treat a variety of human diseases. For the past several years researchers at the Company and the NIH's Institute of Dental and Craniofacial Research have been exploring the vital role of Tb4 in the regeneration, remodeling, and healing of chronic wounds and have published scientific papers on its efficacy in animal models. Several of these researchers will be presenting their results at an International Congress of Allergy and Immunology in New York on April 15, 2001.

The information in this press release may include certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development and commercialization of Tb4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company.

Back To 2001 Press Release Archives